More than 20 years ago, Congress created the 340B Drug Pricing Program to allow eligible hospitals and health systems to stretch limited resources and expand access to care for vulnerable patients. But despite a proven track record of increasing patient access to vital medical services and decreasing government spending, some want changes that would weaken the program.   

340B hospitals continue to help care for low-income and uninsured patients. That is why the AHA sponsored today’s Capitol Hill briefing at which hospitals leaders shared examples of how their 340B programs help their patients and communities. Participating hospitals included Temple University Hospital in Philadelphia; Saint Thomas Health part of Ascension Health in Nashville, Tenn.; Trinity Health in Livonia, Mich.; and Providence Health & Services in Seattle. 

At the briefing, legislators and their staff heard how hospitals use the savings they receive from discounts on high prescription drug prices to reinvest in programs that enhance patient services and access to care.  

They heard how hospitals use 340B savings to provide local access to drugs and treatments for cancer patients, clinical pharmacy services, community outreach programs, free vaccinations, transportation to patients for follow-up appointments and many other services to their communities.   

In August, the Health Resources and Services Administration – the federal agency responsible for administering the 340B program – proposed new policies for the 340 program. Taken together, the changes could jeopardize eligible hospitals’ ability to care for vulnerable patients and communities. 

At the same time, the pharmaceutical industry and its supporters continue to make unsubstantiated claims about the program to persuade Congress to scale it back significantly.  

Hospital leaders are concerned that scaling back the 340B program would force hospitals to curtail or even eliminate services that are essential to keeping patients and communities healthy. Congress should heed the concerns of providers on the front lines of care – and toss aside the arguments of those who wish only to add to the record profits of pharmaceutical companies.

Watch our new video on why the 340B program is so important. And check out all of our 340B resources at www.aha.org/protect340B

Related News Articles

Headline
The Centers for Medicare & Medicaid Services June 20 announced it is finalizing its 2025 Marketplace Integrity and Affordability final rule. The rule…
Headline
A new video in the AHA’s series “Medicaid: Real Lives, Real Care” features insight from Leah Blackwell, R.N., vice president and chief nursing officer at…
Headline
Coalition ad links decisions on Medicaid cuts by Congress to impacts on hospitalsA new television and digital advertisement launched today by the Coalition to…
Perspective
Public
As the Senate eyes a vote next week on its reconciliation bill, the next few days are crucial for reaching out to your senators and urging them to make changes…
Headline
The latest video in the AHA’s series “Medicaid: Real Lives, Real Care” features Becky Pletzer, a licensed clinical social worker from Alaska, explaining why it…
Headline
The Senate Finance Committee June 16 released its draft legislative text as part of the Senate’s version of the budget reconciliation bill. The committee,…